RZLT
Rezolute IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$316.76M
P/E Ratio
—
EPS
$-0.93
Beta
0.66
52W High
$11.46
52W Low
$1.07
50-Day MA
$3.19
200-Day MA
$5.69
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rezolute Inc
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-88.38M |
| Operating Margin | 0.00% |
| Return on Equity | -74.00% |
| Return on Assets | -44.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.23 |
| Price-to-Book | 2.33 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $95.70M |
| Float | $65.46M |
| % Insiders | 10.24% |
| % Institutions | 95.14% |
Historical Volatility
HV 10-Day
64.88%
HV 20-Day
64.08%
HV 30-Day
88.14%
HV 60-Day
90.48%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($5.12 target)
1
Strong Buy6
Buy3
HoldData last updated: 4/28/2026